CAJ | 학술논문

目的探讨应用新活素治疗心肾综合征顽固性心力衰竭的效果. 方法选择我院收治的心肾综合征顽固性心力衰竭患者92作为研究对象并进行分组治疗. 对照组予以血液透析等常规治疗, 研究组在常规治疗的基础上实施新活素治疗. 比较两组患者治疗后的临床表现以及心肾功能改善情况. 结果研究组临床治疗有效率为95.65%, 显著高于对照组的82.61% (P <0.05). 经过治疗后, 两组患者的血浆BNP前体 (NT-pro-BNP) 浓度均显著降低 (P<0.05), 研究组降低幅度显著大于对照组(P<0.05); 两组血肌酐 (Cr) 均显著降低 (P<0.05), 但组间无显著差异 (P>0.05); 两组左室射血分数 (LVEF) 均显著升高(P<0.05), 研究组升高幅度显著大于对照组 (P<0.05). 治疗过程中, 两组患者均未发现药物过敏、低血压及其他的严重不良反应. 结论应用新活素治疗心肾综合征顽固性心力衰竭效果显著, 安全性高, 具有极大的推广应用价值.
목적 탐토응용신활소치료심신종합정완고성심력쇠갈적효과. 방법 선택아원수치적심신종합정완고성심력쇠갈환자92작위연구대상병진행분조치료. 대조조여이혈액투석등상규치료, 연구조재상규치료적기출상실시신활소치료. 비교량조환자치료후적림상표현이급심신공능개선정황. 결과 연구조림상치료유효솔위95.65%, 현저고우대조조적82.61% (P <0.05). 경과치료후, 량조환자적혈장BNP전체 (NT-pro-BNP) 농도균현저강저 (P<0.05), 연구조강저폭도현저대우대조조(P<0.05); 량조혈기항 (Cr) 균현저강저 (P<0.05), 단조간무현저차이 (P>0.05); 량조좌실사혈분수 (LVEF) 균현저승고(P<0.05), 연구조승고폭도현저대우대조조 (P<0.05). 치료과정중, 량조환자균미발현약물과민、 저혈압급기타적엄중불량반응. 결론 응용신활소치료심신종합정완고성심력쇠갈효과현저, 안전성고, 구유겁대적추엄응용개치.
Objective To explore the clinical effect of Xinhuosu for the treatment of patients with refractory heart failure complicated with cardiorenal syndrome. Methods 92 patients with refractory heart failure complicated with cardiorenal syndrome were divided into two groups equally. The control group was given routine therapy, while the research group was given Xinhuosu therapy on the basis of routine therapy. The clinical manifestations and improvement situations of cardiorenal function after therapy were compared. Results The clinical effective rate of research group was 95.65%, significantly higher than 82.61% of control group (P <0.05). After therapy, the level of NT-pro-BNP decreased significantly in both groups (P<0.05), and the research group decreased more significantly than the control group (P<0.05). The level of Cr decreased significantly in both groups (P<0.05), and the declines of two groups had no statistical difference (P>0.05). The level of LVEF increased significantly in both groups (P<0.05), and the research group increased more significantly than the control group (P<0.05). No drug allergy, hypotension, or other serious adverse reaction was found in both groups during therapy. Conclusions Xinhuosu has significant efficacy and safety for the treatment of patients with refractory heart failure complicated with cardiorenal syndrome.